Immunologic adjuvant

Immunologic adjuvant

  • CN 1,909,925 A
  • Filed: 01/19/2005
  • Published: 02/07/2007
  • Est. Priority Date: 02/20/2004
  • Status: Active Grant
First Claim
Patent Images

1. Claim1st, a kind of immunologic adjuvant, is levamisol, or levamisol derivative, or levamisol or levamisol derivative and the composition of following at least one material compositions:

  • White oil, glycerine, oleic acid, double 18 protective embankment base ditallowdimethyl ammonium bromides or saponin.2nd, immunologic adjuvant according to claim 1, it is characterised in that:

    The immunologic adjuvant is levamisol or levamisol derivative.3rd, immunologic adjuvant according to claim 1, it is characterised in that:

    The immunologic adjuvant is the composition of levamisol or levamisol derivative and white oil.4th, immunologic adjuvant according to claim 1, it is characterised in that:

    The immunologic adjuvant is the composition of levamisol or levamisol derivative and glycerine.5th, immunologic adjuvant according to claim 1, it is characterised in that:

    The immunologic adjuvant is the composition of levamisol or levamisol derivative and oleic acid.6th, immunologic adjuvant according to claim 1, it is characterised in that:

    The immunologic adjuvant is the composition of levamisol or levamisol derivative and DDA.7th, immunologic adjuvant according to claim 1, it is characterised in that:

    The immunologic adjuvant is levamisol or levamisol derivative and the composition of saponin.8th, according to any described immunologic adjuvant in claim 1-7, it is characterised in that:

    The levamisol derivative is levamisole hydrochloride or leoamisole phosphate.9th, according to any described immunologic adjuvant in claim 1-7, it is characterised in that:

    The white oil is food white oil or injection white oil.10th, immunologic adjuvant according to claim 3, it is characterised in that:

    The mass ratio of the white oil and levamisol or levamisol derivative is 20;

    1 to 1;

    20.11st, immunologic adjuvant according to claim 10, it is characterised in that:

    The mass ratio of the white oil and levamisol or levamisol derivative is 10;

    1 to 1;

    1.12nd, immunologic adjuvant according to claim 4, it is characterised in that:

    The mass ratio of the glycerine and levamisol or levamisol derivative is 5;

    1 to 1;

    5. '"'"'13rd, immunologic adjuvant according to claim 12, it is characterised in that:

    The mass ratio of the glycerine and levamisol or levamisol derivative is 2;

    1 to 1;

    2.14th, immunologic adjuvant according to claim 5, it is characterised in that:

    The mass ratio of the oleic acid and levamisol or levamisol derivative is 5;

    1 to 1;

    5.15th, immunologic adjuvant according to claim 14, it is characterised in that:

    The mass ratio of the oleic acid and levamisol or levamisol derivative is 2;

    1 to 1;

    2.16th, immunologic adjuvant according to claim 6, it is characterised in that:

    The mass ratio of the DDA and levamisol or levamisol derivative is 20;

    1 to 1;

    20.17th, immunologic adjuvant according to claim 16, it is characterised in that:

    The mass ratio of double 18 protective embankment base ditallowdimethyl ammonium bromides and levamisol or levamisol derivative is 10;

    1 to 1;

    5.18th, immunologic adjuvant according to claim 7, it is characterised in that:

    The mass ratio of the saponin and levamisol or levamisol derivative is 20;

    1 to 1;

    20.19th, immunologic adjuvant according to claim 18, it is characterised in that:

    The mass ratio of the saponin and levamisol or levamisol derivative is 10:

    1 to 1:

    5.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×